Cetera Investment Advisers Increases Stake in Amgen Inc. $AMGN

Cetera Investment Advisers grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.8% during the 1st quarter, HoldingsChannel reports. The firm owned 345,260 shares of the medical research company’s stock after buying an additional 2,800 shares during the period. Cetera Investment Advisers’ holdings in Amgen were worth $121,480,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of AMGN. Dogwood Wealth Management LLC lifted its stake in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares in the last quarter. Anfield Capital Management LLC boosted its position in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after acquiring an additional 70 shares during the last quarter. Tower View Wealth Management LLC grew its stake in Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares in the last quarter. Manning & Napier Advisors LLC grew its stake in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC acquired a new stake in Amgen in the 4th quarter valued at about $33,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is owned by company insiders.

Amgen Price Performance

Amgen stock opened at $371.50 on Friday. The company’s 50 day simple moving average is $350.28 and its 200-day simple moving average is $351.63. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $391.29. The company has a market capitalization of $200.50 billion, a price-to-earnings ratio of 25.85, a price-to-earnings-growth ratio of 3.70 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter last year, the company posted $4.90 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts expect that Amgen Inc. will post 22.31 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AMGN. Royal Bank Of Canada reissued a “positive” rating on shares of Amgen in a research note on Thursday, June 18th. Piper Sandler restated an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Morgan Stanley cut their price target on Amgen from $340.00 to $333.00 and set an “equal weight” rating for the company in a report on Wednesday, July 8th. Canaccord Genuity Group initiated coverage on Amgen in a research report on Monday, April 20th. They set a “hold” rating and a $366.00 price objective on the stock. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $350.00 price objective on shares of Amgen in a research note on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $356.62.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.